Mustafa Naeem, MD
Pulmonary Disease · Tomball, TXNPI 1740243153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 236 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$748
- AstraZeneca$724
- Mylan Specialty L.p.$634
- Shionogi Inc$518
- Regeneron Healthcare Solutions, Inc.$359
- Sanofi$320
- plus $2K from 24 others
Across 196 payments — averaging $4560.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$309K
- AstraZeneca$140K
- Hikma Pharmaceuticals USA$106K
- Sanofi$103K
- Cipla USA Inc.$73K
- Sanofi US Services Inc.$55K
- plus $107K from 3 others
What the payments were for
- Food & beverage$4,821100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $748 |
| AstraZeneca | 37 | $724 |
| Mylan Specialty L.p. | 27 | $634 |
| Shionogi Inc | 25 | $518 |
| Regeneron Healthcare Solutions, Inc. | 16 | $359 |
| Sanofi | 8 | $320 |
| Boehringer Ingelheim | 16 | $272 |
| Supernus Pharmaceuticals, Inc. | 11 | $183 |
| Philips North America LLC | 11 | $181 |
| Viatris Specialty LLC | 4 | $102 |
| Vifor Pharma, Inc. | 5 | $84 |
| Pulmonx Corporation | 3 | $74 |
| Electromed, Inc. | 7 | $70 |
| Biosense Webster, Inc. | 1 | $68 |
| Johnson & Johnson | 3 | $67 |
| Mallinckrodt Hospital Products Inc. | 3 | $64 |
| Inspire Medical Systems, Inc. | 3 | $63 |
| OPKO Pharmaceuticals, LLC | 3 | $44 |
| Insmed, Inc. | 2 | $40 |
| Gilead | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Itamar Medical Inc | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $23 |
| AbbVie | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Pfizer | 1 | $12 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,834 in reported general payments places this provider in the 60th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 450 | $319,587 |
| OfevNintedanib Esylate | 24 | $285,865 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 131 | $85,437 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $15,540 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $10,775 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 199 | $3,897 |
| Roflumilast | 40 | $2,713 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,326 |
| Mometasone Furoate | 26 | $2,056 |
| Levocetirizine Dihydrochloride | 142 | $1,402 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,179 |
| Azelastine Hcl | 40 | $1,120 |
| Ventolin HfaAlbuterol Sulfate | 15 | $822 |
| Cefdinir | 66 | $774 |
| Doxycycline Hyclate | 67 | $642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $748 | $330,362470 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $272 | $301,40550 claims |
| AstraZenecaBreztri Aerosphere | $724 | $85,437131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Tomball
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.